Cubist Pharmaceuticals entered into a research agreement with Evotec. Cubist will use Evotec’s fragment-screening technology, EVOlution™, to complement discovery efforts in two of its antibacterial programs. In addition, Evotec will access the synchrotron technology of Diamond Light Source, its partner for protein crystallography, to determine the 3-D structure of fragments bound to Cubist’s targets of interest.

EVOlution is Evotec’s approach to fragment-based drug discovery. It combines biochemical, nuclear magnetic resonance, and surface plasmon resonance screening technologies for the screening of low molecular weight compounds and fragments. 

This site uses Akismet to reduce spam. Learn how your comment data is processed.